SynthesisBMJ (Clinical research ed.)2015
Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods.
Synthesis in BMJ (Clinical research ed.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
101 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Screening for lung cancer: A systematic review of overdiagnosis and its implications.Molecular oncology · 2026Pooled it
- Screening for breast cancer: a systematic review update to inform the Canadian Task Force on Preventive Health Care guideline.Systematic reviews · 2024Pooled it
- Health benefits and harms of mammography screening in older women (75+ years)-a systematic review.British journal of cancer · 2024Pooled it
- The influence of postscreening follow-up time and participant characteristics on estimates of overdiagnosis from lung cancer screening trials.International journal of cancer · 2022Pooled it
- Assessment of cancer screening effectiveness in the era of screening programs.European journal of epidemiology · 2020Pooled it
- Systematic reviews as a 'lens of evidence': Determinants of benefits and harms of breast cancer screening.International journal of cancer · 2019Pooled it
- Prevalence of incidental breast cancer and precursor lesions in autopsy studies: a systematic review and meta-analysis.BMC cancer · 2017Pooled it
- Assessing the Potential for Patient-led Surveillance After Treatment of Localized Melanoma (MEL-SELF): A Pilot Randomized Clinical Trial.JAMA dermatology · 2022Trial
- Overdiagnosis in atrial fibrillation screening with wearables.Scandinavian journal of primary health care · 2026Article
- Incidence and mortality trends after introduction of lung cancer screening in a community-based healthcare system.Cancer epidemiology · 2026Article
- It depends on where you stand on screening: health professionals' awareness, perspectives, and approaches to overdiagnosis in cancer screening - a qualitative interview study.BMC health services research · 2026Article
- Ten Recommendations for Modelling Cost Effectiveness of Screening: Perspectives of an International Stakeholder Group.PharmacoEconomics · 2026Review
- Prostate-Specific Antigen Screening Patterns and Metastatic Prostate Cancer in US Veterans.JAMA network open · 2026Article
- Empowering patients? The role of self-referral in early cancer detection.The British journal of general practice : the journal of the Royal College of General Practitioners · 2026Article
- The development and application of a novel precise health management model for pulmonary nodules population: a prospective cohort study.Journal of thoracic disease · 2025Article
- General practitioners' clinical decision-making in patients that could have cancer: a vignette study comparing the Baltic states with four Nordic countries.Scandinavian journal of primary health care · 2025Article
- The natural history of ductal carcinoma in situ: development, validation, and estimated outcomes of the SimDCIS model.Breast cancer research and treatment · 2025Article
- Global landscape of early-onset thyroid cancer: current burden, temporal trend and future projections on the basis of GLOBOCAN 2022.Journal of global health · 2025Article
- Global epidemiological trends in the incidence and mortality for melanoma.Skin health and disease · 2025Article
- Impact of patients' age and comorbidities on prostate cancer overdiagnosis in clinical practice.PloS one · 2025Article
41 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveTo determine the optimal method for quantifying and monitoring overdiagnosis in cancer screening over time.
designSystematic review of primary research studies of any design that quantified overdiagnosis from screening for nine types of cancer. We used explicit criteria to critically appraise individual studies and assess strength of the body of evidence for each study design (double blinded review), and assessed the potential for each study design to accurately quantify and monitor overdiagnosis over time. DATA SOURCES: PubMed and Embase up to 28 February 2014; hand searching of systematic reviews. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: English language studies of any design that quantified overdiagnosis for any of nine common cancers (prostate, breast, lung, colorectal, melanoma, bladder, renal, thyroid, and uterine); excluded case series, case reports, and reviews that only reported results of other studies.
results52 studies met the inclusion criteria. We grouped studies into four methodological categories: (1) follow-up of a well designed randomized controlled trial (n=3), which has low risk of bias but may not be generalizable and is not suitable for monitoring; (2) pathological or imaging studies (n=8), drawing conclusions about overdiagnosis by examining biological characteristics of cancers, a simple design limited by the uncertain assumption that the measured characteristics are highly correlated with disease progression; (3) modeling studies (n=21), which can be done in a shorter time frame but require complex mathematical equations simulating the natural course of screen detected cancer, the fundamental unknown question; and (4) ecological and cohort studies (n=20), which are suitable for monitoring over time but are limited by a lack of agreed standards, by variable data quality, by inadequate follow-up time, and by the potential for population level confounders. Some ecological and cohort studies, however, have addressed these potential weaknesses in reasonable ways.
conclusionsWell conducted ecological and cohort studies in multiple settings are the most appropriate approach for quantifying and monitoring overdiagnosis in cancer screening programs. To support this work, we need internationally agreed standards for ecological and cohort studies and a multinational team of unbiased researchers to perform ongoing analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.